[1] THAMPI N,KNIGHT B D,THAVORN K,et al.Health care costs of hospitalization of young children for respiratory syncytial virus infections:a population-based matched cohort study[J].CMAJ Open,2021,9(4):E948-E956.
[2] LI Y,WANG X,BLAU D M,et al.Global,regional,and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019:a systematic analysis[J].Lancet,2022,399(10340):2047-2064.
[3] GÓMEZ-CARBALLA A,PISCHEDDA S,RIVERO-CALLE I,et al.CD14 and related genes in respiratory morbidity after respiratory syncytial virus infection[J].J Infec Dis,2022,226(7):1295-1297.
[4] GATT D,MARTIN I,AlFOUZAN R,et al.Prevention and treatment strategies for respiratory syncytial virus (RSV)[J].Pathogens,2023,12(2):154.
[5] YU J M,FU Y H,PENG X L,et al.Genetic diversity and molecular evolution of human respiratory syncytial virus A and B[J].Sci Rep,2021,11(1):12941.
[6] BOYOGLU-BARNUM S,CHIRKOVA T,ANDERSON L J.Biology of infection and disease pathogenesis to guide RSV vaccine development[J].Front Immunol,2019,10:1675.
[7] TECHAARPORNKUL S,COLLINS P L,PEEPLES M E.Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus[J].Virol,2002,294(2):296-304.
[8] KING T,MEJIAS A,RAMILO O,et al.The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines[J].PLoS Pathogens,2021,17(4):e1009469.
[9] 梁萍,刘瀚旻.呼吸道合胞病毒致病机制的研究进展[J].国际儿科学杂志,2021,48(7):459-463.
[10] SEDEYN K,SCHEPENS B,SAELENS X.Respiratory syncytial virus nonstructural proteins 1 and 2:exceptional disrupters of innate immune responses[J].PLoS Pathogens,2019,15(10):e1007984.
[11] THORNHILL E M,VERHOEVEN D.Respiratory syncytial virus's non-structural proteins:masters of interference[J].Front Cell Infec Microbiol,2020,10:225.
[12] CADENA-CRUZ C,VILLARREAL CAMACHO J L,deÁVILA-ARIAS M,et al.Respiratory syncytial virus entry mechanism in host cells:a general overview[J].Mol Microbiol,2023,120(3):341-350.
[13] CAO D,GAO Y,ROESLER C,et al.Cryo-EM structure of the respiratory syncytial virus RNA polymerase[J].Nat Commu,2020,11(1):368.
[14] LU B,MA C H,BRAZAS R,et al.The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro[J].J Virol,2002,76(21):10776-10784.
[15] HARA K,YAITA K,KHAMRIN P,et al.A small fragmented P protein of respiratory syncytial virus inhibits virus infection by targeting P protein[J].J Gen Virol,2020,101(1):21-32.
[16] DOWNWARD J,YARDEN Y,MAYES E,et al.Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences[J].Nature,1984,307(5951):521-527.
[17] NOH S S,SHIN H J.RSV induces activation of intracellular EGFR on the mitochondrial membrane for virus propagation[J].Int J Mol Sci,2023,24(24):17431.
[18] MONICK M M,CAMERON K,STABER J,et al.Activation of the epidermal growth factor receptor by respiratory syncytial virus results in increased inflammation and delayed apoptosis[J].J Biol Chem,2005,280(3):2147-2158.
[19] NOH S S,SHIN H J.Role of virus-induced EGFR trafficking in proviral functions[J].Biomolecules,2023,13(12):1766.
[20] KALINOWSKI A,GALEN B T,UEKI I F,et al.Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium[J].Mucosal Immunology,2018,11(3):958-967.
[21] GINISTY H,SICARD H,ROGER B,et al.Structure and functions of nucleolin[J].J Cell Sci,1999,112(6):761-772.
[22] TONELLO F,MASSIMINO M L,PEGGION C.Nucleolin:a cell portal for viruses,bacteria,and toxins[J].Cell Mol Life Sci,2022,79(5):271.
[23] GRIFFITHS C D,BILAWCHUK L M,MCDONOUGH J E,et al.IGF1R is an entry receptor for respiratory syncytial virus[J].Nature,2020,583(7817):615-619.
[24] MASTRANGELO P,NORRIS M,DUAN W,et al.Targeting host cell surface nucleolin for RSV therapy:challenges and opportunities[J].Vaccines (Basel),2017,5(3):27.
[25] HAKUNO F,TAKAHASHI S I.40 years of IGF1:IGF1 receptor signaling pathways[J].J Mol Endocrinol,2018,61(1):T69-T86.
[26] KLOUWENBERG P K,TAN L,WERKMAN W,et al.The role of Toll-like receptors in regulating the immune response against respiratory syncytial virus[J].Crit Rev Immunol,2009,29(6):531-550.
[27] WANG D,WANG J.Antiviral immune mechanism of Toll-like receptor 4-mediated human alveolar epithelial cells type Ⅱ[J].Exp Ther Med,2020,20(3):2561-2568.
[28] ZHOU R,LIU L,WANG Y.Viral proteins recognized by different TLRs[J].J Med Virol,2021,93(11):6116-6123.
[29] HUANG Y,JIANG C,LIU X,et al.Melatonin suppresses TLR4-mediated RSV infection in the central nervous cells by inhibiting NLRP3 inflammasome formation and autophagy[J].J Cell Mol Med,2024,28(9):e18338.
[30] CABALLERO M T,SERRA M E,ACOSTA P L,et al.TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization[J].J Clin Invest,2015,125(2):571-582.
[31] STEPHENS L M,VARGA S M.Function and modulation of Type I interferons during respiratory syncytial virus infection[J].Vaccines (Basel),2020,8(2):177.
[32] KIM T H,LEE H K.Innate immune recognition of respiratory syncytial virus infection[J].BMB Reports,2014,47(4):184-191.
[33] MILES M A,LIONG S,LIONG F,et al.TLR7 promotes chronic airway disease in RSV-infected mice[J].Front Immunol,2023,14:1240552.
[34] LEE M,LEE Y,SONG J,et al.Tissue-specific role of CX3CR1 expressing immune cells and their relationships with human disease[J].Immune Netw,2018,18(1):e5.
[35] GREEN G,JOHNSON S M,COSTELLO H,et al.CX3CR1 is a receptor for human respiratory syncytial virus in cotton rats[J].J Virol,2021,95(16):e00010-e00021.
[36] ANDERSON C S,CHU C Y,WANG Q,et al.CX3CR1 as a respiratory syncytial virus receptor in pediatric human lung[J].Pediatr Res,2020,87(5):862-867.
[37] BAGLIVO S J,POLACK F P.The long road to protect infants against severe RSV lower respiratory tract illness[J].F1000Res,2019,8:610.
[38] ANANIA J C,CHENOWETH A M,WINES B D,et al.The human FcγRII (CD32) family of leukocyte FcR in health and disease[J].Front in Immunol,2019,10:464.
[39] WAGNER D K,MUELENAER P,HENDERSON F W,et al.Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first,second,and third infections[J].J Clin Microbiol,1989,27(3):589-592.
[40] HOLGADO M P,RAIDEN S,SANANEZ I,et al.Fcγ receptor iIa (FCGR2A) polymorphism is associated with severe respiratory syncytial virus disease in argentinian infants[J].Front Cell Infec Microbiol,2020,10:607348.
[41] SANANEZ I,RAIDEN S,HOLGADO M P,et al.Upregulation of CD32 in T cells from infants with severe respiratory syncytial virus disease:a new costimulatory pathway?[J].Am J Respir Cell Mol Biol,2020,63(1):133-136.
[42] BOHMWALD K,GÁLVEZ N M S,CANEDO-MARROQUIN G,et al.Contribution of cytokines to tissue damage during human respiratory syncytial virus infection[J].Front Immunol,2019,10:452.
[43] JERSMANN H P.Time to abandon dogma:CD14 is expressed by non-myeloid lineage cells[J].Immunol Cell Biol,2005,83(5):462-467.
[44] BESTEMAN S B,PHUNG E,RAEVEN H H M,et al.Recurrent respiratory syncytial virus infection in a CD14-deficient patient[J].Infect Dis,2022,226(2):258-269.
[45] WEBSTER MARKETON J I,CORRY J,TENG M N.The respiratory syncytial virus (RSV) nonstructural proteins mediate RSV suppression of glucocorticoid receptor transactivation[J].Virology,2014,449:62-69.
[46] BLOODWORTH M H,RUSZNAK M,PFISTER C C,et al.Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology[J].J Allergy Clin Immunol,2018,142(2):683-687.e12.
[47] KAPLAN B L F.Endocannabinoid engagement of CB2 regulates RSV-induced immunity[J].Virulence,2018,9(1):494-495.
[48] LÊ V B,RITEAU B,ALESSI M,et al.Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections[J].Br J Pharmacol,2018,175(2):388-403.
[49] NIKONOVA A A,PICHUGIN A V,CHULKINA M M,et al.The TLR4 agonist immunomax affects the phenotype of mouse lung macrophages during respiratory syncytial virus infection[J].Acta Naturae,2018,10(4):95-99.
[50] LIANG H,LYKINS W R,SEYDOUX E,et al.Formulated phospholipids as non-canonical TLR4 agonists[J].Pharmaceutics,2022,14(2):2557.
[51] DOUDNA J A.The promise and challenge of therapeutic genome editing[J].Nature,2020,578(7794):229-236.
[52] 蔡昌君,黄惠敏,桂冬梅,等.人β-防御素-3调控呼吸道合胞病毒致哮喘幼鼠的气道重塑及白细胞激活[J].东南大学学报(医学版),2022,41(2):183-192.
[53] TAHAMTAN A,ASKARI F S,BONT L,et al.Disease severity in respiratory syncytial virus infection:role of host genetic variation[J].Rev Med Virol,2019,29(2):e2026. |
